Barely Significant
← all excerpts

Biological Treatment of Psoriasis-Data So Far.

Pharmaceuticals (Basel) · 2026 · PMC12944510 · PMID 41754879

Europe PMCDOI
1
hedged sentence
0.0540
closest p · 1.1× alpha
0.0540
boldest claim

The sentences

showed a trendp = 0.054so close (0.05 < p ≤ 0.1)
Similarly, guselkumab showed a trend towards superiority over adalimumab for hands and/or feet psoriasis (82.9% vs. 61.5%, p = 0.054).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.